Novartis Investigative Site

Slaný 274 01

1 studies enrolling now · 5 studies all time

What they study most

Atherosclerosis, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Obesity, Overweight

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed